CCN2 and metabolic dysfunction-associated steatohepatitis: Data demonstrated that targeting CCN2 bioactivity by the CCN2Ab for 10 weeks provided some protective effects against NASH induced by high fat feeding with diabetes, particularly in inflammation markers and in fibrosis end-points.